[15] This signal has not been confirmed in humans, but it is reflected in the prescribing information for approved GLP-1-based medicines such as semaglutide (see the UK Summary of Product Characteristics for Wegovy, available via the electronic Medicines Compendium)
"The novel glucagonagonist component introduces lessunderstood longterm safety considerations, so it is imperative that patients are followed closely by healthcare professionals experienced with this class of medicines, with cautious, stepwise use, despite the impressive efficacy," he cautioned.
Understanding how ibuprofen interacts with semaglutide helps you make informed decisions about pain management during treatment
Always consult with your healthcare provider before starting, switching, or stopping a weight-loss medication
This is normal and usually resolves within 4-6 weeks as the full triple receptor activation establishes itself
However, the widespread publicity and popularity of GLP-1 drugs for weight loss management led to a surge in demand